| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 06/13/2002 | WO2002045738A2 Vaccine composition containing transforming growth factor alpha |
| 06/13/2002 | WO2002045737A2 Methods of treatment involving human mda-7 |
| 06/13/2002 | WO2002045732A1 Proliferation promoters for enteric bifidobacteria |
| 06/13/2002 | WO2002045712A1 Novel method and use |
| 06/13/2002 | WO2002045711A1 Use of anti-muscarinic agents and calcium channel blockers in combination |
| 06/13/2002 | WO2002045702A2 Tricyclic therapeutics for chemokine mediated diseases |
| 06/13/2002 | WO2002045694A1 Rapidly disintegrating tablet comprising an acid-labile active ingredient |
| 06/13/2002 | WO2002045686A2 Pharmaceutical paste comprising an acid-labile active ingredient |
| 06/13/2002 | WO2002045661A1 Use of moulding compounds for producing treatment devices |
| 06/13/2002 | WO2002026929A3 Kini-3 motor protein and methods for its use |
| 06/13/2002 | WO2002012245A3 Azabicyclic derivatives and their therapeutic use |
| 06/13/2002 | WO2002003962A3 Drug delivery system for poorly water soluble drugs |
| 06/13/2002 | WO2002000657A3 Condensed pyrazindione derivatives |
| 06/13/2002 | WO2001094415A3 Nuclear hormone receptor |
| 06/13/2002 | WO2001090104A3 -(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases |
| 06/13/2002 | WO2001028538A3 Laxative preparation containing l-arginine |
| 06/13/2002 | US20020072735 Multi-step drug dosage forms |
| 06/13/2002 | US20020072631 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 06/13/2002 | US20020072630 Therapy |
| 06/13/2002 | US20020072616 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| 06/13/2002 | US20020072534 20- Hete antagonists and agonists |
| 06/13/2002 | US20020072529 For therapy and prophylaxis of cerebral apoplexy and craniocerebral trauma |
| 06/13/2002 | US20020072525 Aryl fused azapolycyclic compounds |
| 06/13/2002 | US20020072524 Aryl fused azapolycyclic compounds |
| 06/13/2002 | US20020072523 For therapy of inflammatory and immune diseases |
| 06/13/2002 | US20020072517 Substituted cyclic amine metalloprotease inhibitors |
| 06/13/2002 | US20020072500 3-(carboxy(hydroxy)alkylaminocarbonylmethylaminocarbonyl), 5-(tetrahydropyrimidin-2-yl-amino)phenol for example |
| 06/13/2002 | US20020072499 Specifically an N-formyl-methionyl-leucyl ("f-Met-Leu") tri-or tetra-peptide; pathological fibrosis or those caused by trauma or surgery |
| 06/13/2002 | US20020072494 Angiogenesis inhibitor, K1-5 (protease-activated kringles 1-5) genetically engineered so it can be secreted from cells in which it is expressed; contains a secretory signal peptide and a pre-activation peptide derived from plasminogen |
| 06/13/2002 | US20020072119 Preventing tumor growth; obtain cells, transform with expression vector, monitor cells for reduction in cell proliferation |
| 06/13/2002 | US20020072101 Novel human nucleic acid molecules and polypeptides encoding cation channels |
| 06/13/2002 | US20020071872 Laxative composition |
| 06/13/2002 | US20020071843 Targeted therapeutic agents |
| 06/13/2002 | US20020071835 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications |
| 06/13/2002 | US20020071822 Polymer comprising a backbone comprising ester, thioester, or amide linkages, and wherein the backbone comprises one or more groups that will yield a biologically active compound upon hydrolysis of the polymer. |
| 06/13/2002 | DE10061334A1 Verwendung von aus embryonalen Stammzellen hergeleiteten Zellen zur Erhöhung der Transplantationstoleranz und zur Wiederherstellung zerstörten Gewebes Using derived from embryonic stem cells to increase transplant tolerance and restore damaged tissue |
| 06/13/2002 | CA2436984A1 Urea substituted imidazoquinoline ethers |
| 06/13/2002 | CA2436983A1 Sulfonamido ether substituted imidazoquinolines |
| 06/13/2002 | CA2436899A1 Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines |
| 06/13/2002 | CA2436870A1 Substituted anthranilic acids |
| 06/13/2002 | CA2436732A1 Protein modification and maintenance molecules |
| 06/13/2002 | CA2436601A1 Perturbed membrane-binding compounds |
| 06/13/2002 | CA2435467A1 Benzyl (idene)-lactams and their use as 5ht1-receptor ligands |
| 06/13/2002 | CA2431203A1 Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor |
| 06/13/2002 | CA2431151A1 Heterocyclic ether substituted imidazoquinolines |
| 06/13/2002 | CA2431002A1 Zinc containing dentifrice of reduced astringency |
| 06/13/2002 | CA2430993A1 G-protein coupled receptors |
| 06/13/2002 | CA2430966A1 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
| 06/13/2002 | CA2430844A1 Aryl ether substituted imidazoquinolines |
| 06/13/2002 | CA2430621A1 Vaccine composition containing transforming growth factor alpha |
| 06/13/2002 | CA2430558A1 Proteins and nucleic acids encoding same |
| 06/13/2002 | CA2430412A1 Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors |
| 06/13/2002 | CA2430206A1 Screening method for identifying compounds that selectively induce interferon alpha |
| 06/13/2002 | CA2429769A1 Methods of treatment involving human mda-7 |
| 06/13/2002 | CA2429641A1 Kinases and phosphatases |
| 06/13/2002 | CA2429258A1 Piperidine/piperazine-type inhibitors of p38 kinase |
| 06/13/2002 | CA2428390A1 Enzymes |
| 06/13/2002 | CA2428208A1 Lipid-associated molecules |
| 06/13/2002 | CA2428092A1 Use of sarp-1 for the treatment and/or prevention of scleroderma |
| 06/12/2002 | EP1213297A1 Novel tachykinin peptides, precursor peptides thereof and genes encoding the same |
| 06/12/2002 | EP1213291A1 Spiro [1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine for use in the treatment of psychotic and intellectual impairment disorders |
| 06/12/2002 | EP1213289A1 N-benzenesulfonyl L-proline compounds as bradykinin antagonists |
| 06/12/2002 | EP1213285A2 4,5-dipheny-oxazole derivatives and their use as platelet aggregation inhibitors |
| 06/12/2002 | EP1213281A1 Novel amide derivatives |
| 06/12/2002 | EP1213029A1 Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
| 06/12/2002 | EP1213027A2 Liver function protecting or improving agent |
| 06/12/2002 | EP1213015A1 Oral pharmaceutical composition with delayed release of proton pump inhibitors |
| 06/12/2002 | EP1212941A2 Modulating ramp activity |
| 06/12/2002 | EP1212436A2 Protein phosphatase and kinase proteins |
| 06/12/2002 | EP1212433A2 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 06/12/2002 | EP1212418A2 p193 PROTEINS AND NUCLEIC ACIDS, AND USES THEREOF |
| 06/12/2002 | EP1212416A2 Nucleic acid based modulators of gene expression |
| 06/12/2002 | EP1212363A2 Il-16 antagonists |
| 06/12/2002 | EP1212344A1 B7-like polynucleotides, polypeptides, and antibodies |
| 06/12/2002 | EP1212329A2 Amine derivatives of benzo[4,5]thieno[2,3-d]pyrimidine |
| 06/12/2002 | EP1212328A1 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 06/12/2002 | EP1212327A2 Pyrazolopyrimidines as therapeutic agents |
| 06/12/2002 | EP1212323A2 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| 06/12/2002 | EP1212320A2 Phenylpiperazines as serotonin reuptake inhibitors |
| 06/12/2002 | EP1212319A2 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
| 06/12/2002 | EP1212317A1 Indole derivatives and their use for the treatment of osteoporosis amongst other applications |
| 06/12/2002 | EP1212309A1 Caspase inhibitor |
| 06/12/2002 | EP1212305A2 1,5-benzodiazepine derivatives as cck-a receptor agonists |
| 06/12/2002 | EP1212299A1 Substituted piperidine compounds useful as modulators of chemokine receptor activity |
| 06/12/2002 | EP1212087A1 Methods and compositions utilizing rad51 |
| 06/12/2002 | EP1212086A1 Immunological tolerance-induction agent |
| 06/12/2002 | EP1212084A2 Method of separating rotavirus variants and live attenuated rotavirus vaccine |
| 06/12/2002 | EP1212077A2 Pharmaceutical composition of nateglinide and another antidiabetic agent |
| 06/12/2002 | EP1212070A1 Plant extract mixtures and their uses |
| 06/12/2002 | EP1212065A1 Compositions and methods for raising hdl cholesterol levels |
| 06/12/2002 | EP1212063A2 Topical azathioprine for the treatment of oral autoimmune diseases |
| 06/12/2002 | EP1212062A1 Use of thienopyrimidines |
| 06/12/2002 | EP1212050A2 Formulations containing tetracyclinesfor treating or preventing mucositis |
| 06/12/2002 | EP1212041A1 Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins |
| 06/12/2002 | EP1212040A1 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties |
| 06/12/2002 | EP1212039A1 Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent |
| 06/12/2002 | EP1105386B1 Novel salt form of pantoprazole |
| 06/12/2002 | EP1039922B1 Improved interferon polymer conjugates |
| 06/12/2002 | EP1032571B1 Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists |
| 06/12/2002 | EP1028947B1 H3 receptor ligands of the phenyl-alkyl-imidazoles type |